S. Jordan Associates
- Investment bank
S. Jordan Associates (SJA) is a boutique investment banking firm focused exclusively on the life sciences sector, including biotechnology, diagnostics, and medical devices. The firm provides end-to-end advisory services to emerging and growth-stage private companies seeking licensing partners with large pharma, private placements / PIPES, public listings on major stock exchanges via Alternative Public Offerings (APOs) including reverse mergers, and strategies for meeting listing requirements / uplistings.
Since inception, SJA has raised $155M of private placements, closed $583M in licensing deals, and secured $194M via public offerings (IPO / Reverse Merger) including listing Salarius Pharmaceuticals on NASDAQ in 2019.
SJA is representing Barricade Therapeutics who is developing a novel small molecule EBP inhibitor drug that targets the key APC mutation associated with Colorectal Cancer (CRC). This mutation is prevalent in 80% of CRC patients.